FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891954998> ?p ?o ?g. }

• W2891954998 endingPage "5083" @default.
• W2891954998 startingPage "5083" @default.
• W2891954998 abstract "5083 Background: PSA-TRICOM (Prostvac) is a vector-based vaccine designed to generate a robust immune response (IR) against PSA–expressing tumor cells. To date, studies of Prostvac in patients with mCRPC have shown IR in peripheral blood but effects on prostate tumors are unknown. Methods: An open label phase 2 study of neoadjuvant Prostvac (NCT02153918) enrolled patients (pts) with localized prostate cancer undergoing radical prostatectomy (RP). Priming vaccination was given followed by boosts on days 15, 29 and 57 prior to RP (~day 64). The 1° objective evaluated increases in CD4 and CD8 cell infiltrate (RP tissue vs. baseline biopsies) by IHC. IR to tumor associated antigens (TAA) was measured using intracellular cytokine staining (ICS) in PBMC from baseline and ~day 63. Results: 27 pts (median age 64.8 years) enrolled. All pts received 4 pre-RP vaccine injections. Matched tissue IHC analysis and peripheral IR is available on 24 pts. TAA specific T cell peripheral IR to PSA, Muc-1 or Brachyury were observed in 12/24 (50%) pts post vaccine, with 25% of pts responding to each antigen. Table comparing peripheral IR vs. tumoral IR. Clinical trial information: NCT02153918. 19 pts were evaluable for tissue RNA expression profiles pre/post vaccine and observed upregulation of genes such as RANKL (DC maturation), CCL25 (chemotaxis), and FLT3 (T-cell development) suggests vaccine-induced IRs. Conversely, increased expression of immunosuppressive genes (e.g., FOXP3, IL-10) suggests adaptive resistance post vaccination. Conclusions: Prostvac treatment is associated with a ≥2X increase in CD8 and CD4 intra/ peritumoral infiltrate in 17/24 and 21/24 pts, respectively. However only 12/24 had a TAA response in the peripheral blood. Anti-tumor IRs may become broader and more immunologically relevant over time (Ag spreading) and may be underestimated by peripheral IRs to TAA. These data better inform the immunodynamic effects of Prostvac which are incompletely represented by peripheral IR data. Work is ongoing to more fully characterize the IR with multispectral imaging, targeted RNASeq and TCRSeq analysis. ↑ CD8 Infiltrate ↑ CD4 Infiltrate No Yes No Yes No Peripheral IR 5 7 2 10 Peripheral IR 2 10 1 11 Total 17/24 21/24" @default.
• W2891954998 created "2018-09-27" @default.
• W2891954998 creator A5023803946 @default.
• W2891954998 creator A5027334479 @default.
• W2891954998 creator A5036982892 @default.
• W2891954998 creator A5038850729 @default.
• W2891954998 creator A5040286491 @default.
• W2891954998 creator A5044285326 @default.
• W2891954998 creator A5046300035 @default.
• W2891954998 creator A5047746288 @default.
• W2891954998 creator A5052157883 @default.
• W2891954998 creator A5052810568 @default.
• W2891954998 creator A5059931764 @default.
• W2891954998 creator A5060932746 @default.
• W2891954998 creator A5065550926 @default.
• W2891954998 creator A5070669850 @default.
• W2891954998 creator A5074041292 @default.
• W2891954998 creator A5091182708 @default.
• W2891954998 date "2018-05-20" @default.
• W2891954998 modified "2023-09-30" @default.
• W2891954998 title "Effect of rilimogene galvacirepvec/rilimogene glafolivec on intra/peritumoral immune infiltrate in patients with localized prostate cancer undergoing radical prostatectomy." @default.
• W2891954998 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.5083" @default.
• W2891954998 hasPublicationYear "2018" @default.
• W2891954998 type Work @default.
• W2891954998 sameAs 2891954998 @default.
• W2891954998 citedByCount "2" @default.
• W2891954998 countsByYear W28919549982021 @default.
• W2891954998 countsByYear W28919549982022 @default.
• W2891954998 crossrefType "journal-article" @default.
• W2891954998 hasAuthorship W2891954998A5023803946 @default.
• W2891954998 hasAuthorship W2891954998A5027334479 @default.
• W2891954998 hasAuthorship W2891954998A5036982892 @default.
• W2891954998 hasAuthorship W2891954998A5038850729 @default.
• W2891954998 hasAuthorship W2891954998A5040286491 @default.
• W2891954998 hasAuthorship W2891954998A5044285326 @default.
• W2891954998 hasAuthorship W2891954998A5046300035 @default.
• W2891954998 hasAuthorship W2891954998A5047746288 @default.
• W2891954998 hasAuthorship W2891954998A5052157883 @default.
• W2891954998 hasAuthorship W2891954998A5052810568 @default.
• W2891954998 hasAuthorship W2891954998A5059931764 @default.
• W2891954998 hasAuthorship W2891954998A5060932746 @default.
• W2891954998 hasAuthorship W2891954998A5065550926 @default.
• W2891954998 hasAuthorship W2891954998A5070669850 @default.
• W2891954998 hasAuthorship W2891954998A5074041292 @default.
• W2891954998 hasAuthorship W2891954998A5091182708 @default.
• W2891954998 hasConcept C121608353 @default.
• W2891954998 hasConcept C126322002 @default.
• W2891954998 hasConcept C147483822 @default.
• W2891954998 hasConcept C167672396 @default.
• W2891954998 hasConcept C203014093 @default.
• W2891954998 hasConcept C2776090121 @default.
• W2891954998 hasConcept C2777701055 @default.
• W2891954998 hasConcept C2779466945 @default.
• W2891954998 hasConcept C2779727006 @default.
• W2891954998 hasConcept C2780192828 @default.
• W2891954998 hasConcept C71924100 @default.
• W2891954998 hasConcept C8891405 @default.
• W2891954998 hasConceptScore W2891954998C121608353 @default.
• W2891954998 hasConceptScore W2891954998C126322002 @default.
• W2891954998 hasConceptScore W2891954998C147483822 @default.
• W2891954998 hasConceptScore W2891954998C167672396 @default.
• W2891954998 hasConceptScore W2891954998C203014093 @default.
• W2891954998 hasConceptScore W2891954998C2776090121 @default.
• W2891954998 hasConceptScore W2891954998C2777701055 @default.
• W2891954998 hasConceptScore W2891954998C2779466945 @default.
• W2891954998 hasConceptScore W2891954998C2779727006 @default.
• W2891954998 hasConceptScore W2891954998C2780192828 @default.
• W2891954998 hasConceptScore W2891954998C71924100 @default.
• W2891954998 hasConceptScore W2891954998C8891405 @default.
• W2891954998 hasIssue "15_suppl" @default.
• W2891954998 hasLocation W28919549981 @default.
• W2891954998 hasOpenAccess W2891954998 @default.
• W2891954998 hasPrimaryLocation W28919549981 @default.
• W2891954998 hasRelatedWork W1548495996 @default.
• W2891954998 hasRelatedWork W1974496092 @default.
• W2891954998 hasRelatedWork W1996150995 @default.
• W2891954998 hasRelatedWork W2220102944 @default.
• W2891954998 hasRelatedWork W2366649094 @default.
• W2891954998 hasRelatedWork W2409441623 @default.
• W2891954998 hasRelatedWork W3167775801 @default.
• W2891954998 hasRelatedWork W4210976760 @default.
• W2891954998 hasRelatedWork W4313369199 @default.
• W2891954998 hasRelatedWork W4360983034 @default.
• W2891954998 hasVolume "36" @default.
• W2891954998 isParatext "false" @default.
• W2891954998 isRetracted "false" @default.
• W2891954998 magId "2891954998" @default.
• W2891954998 workType "article" @default.